- Home
- NAAS vs RLYB Comparison
NAAS vs RLYB Comparison
Compare NAAS & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAAS | RLYB |
|---|---|---|
| Founded | 2019 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.4M | 28.7M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NAAS | RLYB |
|---|---|---|
| Price | $2.04 | $10.66 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.8K | ★ 201.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $600,000.00 |
| Revenue This Year | $378.49 | $17.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $0.22 |
| 52 Week High | $4.54 | $11.20 |
Technical Indicators
Market Signals| Indicator | NAAS | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 31.52 | 92.99 |
| Support Level | $0.55 | $0.48 |
| Resistance Level | $3.77 | N/A |
| Average True Range (ATR) | 0.12 | 0.76 |
| MACD | -0.01 | 0.55 |
| Stochastic Oscillator | 30.00 | 89.39 |
Price Performance
Historical ComparisonAbout NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.